{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:41:26Z","timestamp":1700674886345},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s12094-008-0293-7","type":"journal-article","created":{"date-parts":[[2008,12,19]],"date-time":"2008-12-19T14:14:24Z","timestamp":1229696064000},"page":"804-811","source":"Crossref","is-referenced-by-count":3,"title":["Human papillomavirus vaccine and cervical cancer prevention"],"prefix":"10.1007","volume":"10","author":[{"given":"Ana","family":"Oaknin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pilar Barretina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,20]]},"reference":[{"key":"293_CR1","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","volume":"118","author":"D.M. Pakin","year":"2006","unstructured":"Pakin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030\u20133044","journal-title":"Int J Cancer"},{"key":"293_CR2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"D.M. Pakin","year":"2005","unstructured":"Pakin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"293_CR3","volume-title":"Handbooks of cancer prevention: cervix cancer screening, Vol. 10","author":"International Agency for Research on Cancer","year":"2005","unstructured":"International Agency for Research on Cancer (IARC) (2005) Handbooks of cancer prevention: cervix cancer screening, Vol. 10. IARC, Lyon, France"},{"key":"293_CR4","volume-title":"SEER cancer statistics review. 1975\u20132003: National Cancer Institute","author":"L. Ries","year":"2006","unstructured":"Ries L, Harkins D, Krapcho M et al (2006) SEER cancer statistics review. 1975\u20132003: National Cancer Institute. National Cancer Institute, Bethesda, MD"},{"key":"293_CR5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/00003081-199912000-00020","volume":"42","author":"G.F. Sawaya","year":"1999","unstructured":"Sawaya GF, Washington AE (1999) Cervical cancer screening: which techniques should be used and why? Clin Obstet Gynecol 42: 922\u2013938","journal-title":"Clin Obstet Gynecol"},{"key":"293_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","volume":"102","author":"L. Koutsky","year":"1997","unstructured":"Koutsky L (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102:3\u20138","journal-title":"Am J Med"},{"key":"293_CR7","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/oxfordjournals.aje.a010166","volume":"151","author":"E.R. Myers","year":"2000","unstructured":"Myers ER, McCrory DC, Nanda K et al (2000) Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151:1158\u20131171","journal-title":"Am J Epidemiol"},{"key":"293_CR8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM199802123380703","volume":"338","author":"G.Y. Ho","year":"1998","unstructured":"Ho GY, Bierman R, Beardsley L et al (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423\u2013428","journal-title":"N Engl J Med"},{"key":"293_CR9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","volume":"121","author":"J.S. Smith","year":"2007","unstructured":"Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high grade cervical lesions: a meta-analysis update. Int J Cancer 121:621\u2013632","journal-title":"Int J Cancer"},{"key":"293_CR10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N. Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz N, Bosch FX, de Sanjose S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518\u2013527","journal-title":"N Engl J Med"},{"key":"293_CR11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0002-9378(99)70256-5","volume":"180","author":"A. Hildesheim","year":"1999","unstructured":"Hildesheim A, Hadjimichael O, Schwartz PE et al (1999) Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 180:571\u2013577","journal-title":"Am J Obstet Gynecol"},{"key":"293_CR12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/89.17.1285","volume":"89","author":"N. Dyson","year":"1997","unstructured":"Dyson N, Howley PM, Munger K et al (1997) Proliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 89:1285\u20131293","journal-title":"J Natl Cancer Inst"},{"key":"293_CR13","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ygyno.2008.02.003","volume":"109","author":"M. Stanley","year":"2008","unstructured":"Stanley M (2008) Immunobiology of HPV and HPV vaccines. Gynecol Oncol 109:S15\u2013S21","journal-title":"Gynecol Oncol"},{"key":"293_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2050","volume":"7","author":"C.B. Woodman","year":"2007","unstructured":"Woodman CB, Collins S, Young L (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7:11\u201322","journal-title":"Nat Rev Cancer"},{"key":"293_CR15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jnci\/djj067","volume":"98","author":"X. Castellsague","year":"2006","unstructured":"Castellsague X, Diaz M, Sanjose S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98:303\u2013315","journal-title":"J Natl Cancer Inst"},{"key":"293_CR16","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ygyno.2007.07.068","volume":"107","author":"M. Stanley","year":"2007","unstructured":"Stanley M (2007) Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 107:S19\u2013S23","journal-title":"Gynecol Oncol"},{"key":"293_CR17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.67.1.315-322.1993","volume":"67","author":"M.E. Hagensee","year":"1993","unstructured":"Hagensee ME, Yaegashi N, Galloway DA (1993) Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67:315\u2013322","journal-title":"J Virol"},{"key":"293_CR18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","volume":"93","author":"C.D. Harro","year":"2001","unstructured":"Harro CD, Pang YY, Roden RB et al (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93:284\u2013292","journal-title":"J Natl Cancer Inst"},{"key":"293_CR19","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","volume":"347","author":"L.A. Koutsky","year":"2002","unstructured":"Koutsky LA, Kevin A, Wheeler CM et al (2002) A controlled trial of a human papillomavirus Type 16 vaccine. N Engl J Med 347:1645\u20131651","journal-title":"N Engl J Med"},{"key":"293_CR20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","volume":"6","author":"L.L. Villa","year":"2005","unstructured":"Villa LL, Costa RLR, Petta CA et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271\u2013278","journal-title":"Lancet Oncol"},{"key":"293_CR21","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"FUTURE II Study Group","year":"2007","unstructured":"FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915\u20131927","journal-title":"N Engl J Med"},{"key":"293_CR22","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"FUTURE I Study Group","year":"2007","unstructured":"FUTURE I Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928\u20131943","journal-title":"N Engl J Med"},{"key":"293_CR23","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","volume":"364","author":"D.M. Harper","year":"2004","unstructured":"Harper DM, Franco EL, Wheeler C et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a ran domised controlled trial. Lancet 364:1757\u20131765","journal-title":"Lancet"},{"key":"293_CR24","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"D.M. Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler C et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247\u20131255","journal-title":"Lancet"},{"key":"293_CR25","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J. Paavonen","year":"2007","unstructured":"Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161\u20132170","journal-title":"Lancet"},{"key":"293_CR26","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","volume":"24","author":"L.L. Villa","year":"2006","unstructured":"Villa LL, Ault KA, Giuliano AR et al (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24:5571\u20135583","journal-title":"Vaccine"},{"key":"293_CR27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","volume":"95","author":"L.L. Villa","year":"2006","unstructured":"Villa LL, Costa RLR, Petta CA et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6, 11,16, and 18 L1 virus-like-particle vaccine through 5 years of follow up. Br J Cancer 95:1459\u20131466","journal-title":"Br J Cancer"},{"key":"293_CR28","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","volume":"369","author":"FUTURE II Study Group","year":"2007","unstructured":"FUTURE II Study Group (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade2, grade3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861\u20131868","journal-title":"Lancet"},{"key":"293_CR29","first-page":"S3233","volume":"24S3","author":"M. Lehtinen","year":"2006","unstructured":"Lehtinen M, Herrero R, Mayaud P et al (2006) Studies to asses the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24S3:S3233\u20133241","journal-title":"Vaccine"},{"key":"293_CR30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.57.1.7","volume":"57","author":"D. Saslow","year":"2007","unstructured":"Saslow D, Castle PE, Cox JT et al (2007) American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57:7\u201328","journal-title":"CA Cancer J Clin"},{"key":"293_CR31","first-page":"1","volume":"362","author":"W.D. Mosher","year":"2005","unstructured":"Mosher WD, Chandra A, Jones J (2005) Sexual behaviour and selected health measures: men and women 15\u201344 years of age, United States, 2002. Adv Data 362:1\u201355","journal-title":"Adv Data"},{"key":"293_CR32","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.ygyno.2008.01.004","volume":"109","author":"K.H. Warner","year":"2008","unstructured":"Warner KH, Richard BS (2008) The future of vaccines for cervical cancer. Gynecol Oncol 109: S48\u201356","journal-title":"Gynecol Oncol"},{"key":"293_CR33","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMe078060","volume":"356","author":"G.F. Sawaya","year":"2008","unstructured":"Sawaya GF, Smith-McCune K (2008) HPV vaccination \u2014 more answers, more questions. N Engl J Med 356:1991\u20131993","journal-title":"N Engl J Med"},{"key":"293_CR34","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2007.10.8662","volume":"25","author":"J.K. Chan","year":"2007","unstructured":"Chan JK, Berek JS (2007) Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 25:2975\u20132982","journal-title":"J Clin Oncol"},{"key":"293_CR35","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMp078053","volume":"356","author":"J.M. Agosti","year":"2007","unstructured":"Agosti JM, Goldie SJ (2007) Introducing HPV vaccine in developing countries \u2014 key challenges and issues. N Engl J Med 356:1908\u20131910","journal-title":"N Engl J Med"},{"key":"293_CR36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jnci\/dji072","volume":"97","author":"G.M. Clifford","year":"2005","unstructured":"Clifford GM, Polesel J, Rickenbach M et al (2005) Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97:425\u2013432","journal-title":"J Natl Cancer Inst"},{"key":"293_CR37","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","volume":"359","author":"J.J. Kim","year":"2008","unstructured":"Kim JJ, Goldie SJ (2008) Health and economic implications of HPV vaccination in the United States. N Engl J Med 359:821\u2013832","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-008-0293-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-008-0293-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-008-0293-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:03:22Z","timestamp":1589414602000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-008-0293-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1007\/s12094-008-0293-7","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}